LL-37: Preliminary Phase II data

Preliminary data from a double-blind, Swedish Phase I/II trial in 34 patients with venous leg ulcers showed that LL-37 for 1 month was well tolerated at the 0.5 and 1.6 mg/mL doses, but led to an incr...